Hangzhou Tigermed: A Genuine China CRO Recovery, Priced Ahead of Clean Earnings

Company vertical history

Origins and listing path

Tigermed was founded in Hangzhou in 2004, at a time when China’s outsourced drug-development infrastructure was still thin and domestic innovative-drug development was far less mature than it is today. The company’s own 2020 annual report framed its mission around providing full-process clinical trial services for new-drug development, and its later H-share prospectus marketed the business as a China-based CRO that could compress timelines, reduce development risk, and serve both domestic innovators and international sponsors. The founders remain central to the story: the 2025 annual report shows Ye Xiaoping and Cao Xiaochun still as the actual controllers, holding about 20.49% and 5.96% respectively at year-end 2025.

The IPO path came in two stages, and those two listings map the company’s two identities. The A-share IPO on Shenzhen’s ChiNext came first, with the company issuing 13.4 million shares at RMB 37.88 on 2012-08-17. The H-share listing followed much later, on 2020-08-07, when Tigermed offered 107.07 million H shares at HKD 100 apiece on HKEX’s Main Board. The domestic listing funded scale-up inside China. The Hong Kong listing funded globalization and gave the company a larger capital-markets base just as China biotech still enjoyed a powerful financing boom.

Stages of development

The first stage, from founding through the A-share listing, was about proving that a domestic independent CRO could exist at all in a market that still leaned heavily on multinational pharma standards and fragmented local execution. The company solved a coordination problem more than a technology problem. Sponsors needed site networks, protocol execution, monitoring, and regulatory know-how that were localized enough for China but credible enough for global-quality development. That early role still explains why Tigermed’s identity remains rooted in clinical execution rather than manufacturing or platform software.

The second stage, from roughly 2012 through 2019, was the domestic land-grab. Tigermed expanded trial management, site services, data management, statistics, and related consulting while China’s drug-approval system reformed and local biotech activity accelerated. By the company’s own later citing of Frost & Sullivan, it maintained the largest market share in China’s clinical CRO industry and claimed services related to 61% of China’s Class I new-drug approvals from 2004 through 2025. The point is not that every percentage in a company slide should be taken as gospel. The point is that Tigermed spent that period becoming embedded in the everyday work of Chinese drug development.

The third stage, from 2020 through 2021, was the internationalization and balance-sheet expansion phase. The HKEX listing raised fresh capital near the height of investor enthusiasm for biopharma outsourcing. The company used that period to strengthen overseas capabilities, deepen its relationship with Frontage, and push beyond “China clinical CRO” into a more diversified services platform. This was the stage when the market paid the highest narrative multiple, because investors believed China’s innovative-drug financing cycle, local R&D productivity, and outsourcing penetration would all compound together for years.

The fourth stage, from 2022 through 2025, was a reset. China biotech funding cooled. Domestic pricing pressure emerged. Laboratory utilization became a bigger issue, especially in businesses expanded ahead of demand. The annual report says the clinical-trial-solutions segment generated RMB 3.27 billion of revenue in 2025 with only a 20.09% gross margin, down 9.47 percentage points year on year, while clinical-related and laboratory services earned RMB 3.45 billion at a 32.64% margin, down 4.20 points. The annual-results presentation shows total gross margin fell from 34.0% in 2024 to 27.4% in 2025. This was not a collapse in revenue. It was a collapse in incremental profitability.

The fifth stage, which began to show in 2025 and is still incomplete in 2026, is the early-recovery stage with a governance overhang. Bookings and backlog grew again. Overseas execution continued to widen. In July 2025 Tigermed announced the acquisition of Japanese CRO Micron, adding imaging analysis and local Japanese delivery capability. The company also expanded teams in India and Malaysia. Yet the same recovery phase was interrupted by the May 2026 case-filing notices to the founders. So this is a stage in which operating indicators have turned up before valuation confidence has fully returned.

Key nodes that still matter

The 2020 H-share IPO still matters because it changed what Tigermed could try to become. Without that capital and profile jump, it would have been much harder to finance overseas hiring, acquisitions, and the larger laboratory-service footprint that now supports overseas mix growth. In hindsight, the market overrated the speed and smoothness of the post-IPO earnings ramp, but it did not overrate the strategic logic of widening the platform.

The build-out of Frontage and related laboratory services matters too, though in a more mixed way. In 2025 Frontage generated RMB 1.83 billion of revenue but only RMB 48.25 million of net profit, according to the subsidiary summary in the annual report. That tells the story in one line: the lab and nonclinical side gives Tigermed breadth and customer access, but not all of that breadth has produced attractive returns at the same pace. The annual report also says utilization of facilities built in earlier years continued to improve in 2025, which suggests the drag may be cyclical rather than permanent.

The investment-book expansion is a quieter but equally important node. Tigermed’s large holdings in other non-current financial assets, its associate and fund exposures, and the contribution from investment income have made reported earnings more volatile and harder to read. In 2025 it recorded RMB 433.8 million of investment income and RMB 42.3 million of fair-value gain; non-recurring gains added RMB 532.8 million in total after tax. At the same time, the company’s important associate Hangzhou Taikun Equity Investment Fund contributed RMB 421.3 million of net profit at the fund level, with Tigermed receiving RMB 187.9 million of dividends in the year. This has supported balance-sheet flexibility, but it has also blurred the earnings signal investors most care about: clean CRO operating profit.

The May 2026 founder investigation is the latest node, and it still carries force because governance discounts rarely disappear in one quarter. The company said the matter related to historical shareholding-change disclosure and not ongoing operations. That helps on business continuity. It does not remove the possibility that domestic investors will now apply a more skeptical multiple to future recoveries. The market often forgives cyclical misses faster than it forgives disclosure problems.

Financial vertical review

The long financial arc is a story of revenue resilience, margin compression, and earnings distortion. Revenue went from RMB 7.38 billion in 2023 to RMB 6.60 billion in 2024 and back to RMB 6.83 billion in 2025. That is not a high-growth line anymore, but it also is not a broken one. Reported attributable profit fell from RMB 2.02 billion in 2023 to RMB 405.1 million in 2024, then rebounded to RMB 887.9 million in 2025. Adjusted attributable profit, though, dropped from RMB 1.48 billion in 2023 to RMB 854.9 million in 2024 and then to RMB 355.1 million in 2025. The gap between reported and adjusted profit is the whole earnings-quality problem in numbers.

Cash generation has held up better than clean profit. Operating cash flow was RMB 1.15 billion in 2023, RMB 1.10 billion in 2024, and RMB 1.12 billion in 2025. That means cash conversion against adjusted profit looked sound in 2024 and better still in 2025, even as accounting earnings looked weak. The service model helps here: Tigermed is not a capital-heavy manufacturer at the core level, even though labs and acquisitions do add fixed-cost weight. This is why the company is not in a liquidity squeeze. The strain is on return quality, not on survival.

The balance sheet is still healthy enough for the current strategy. At 2025 year-end, total assets were RMB 28.36 billion and equity attributable to the parent was RMB 20.96 billion. The first-quarter 2026 report showed total assets at RMB 28.80 billion and parent equity at RMB 20.92 billion. That is a strong capital base for a services business. Short-term borrowings existed, including foreign-currency borrowings disclosed in the annual report, but leverage is not the central risk. The larger questions are whether capital is being allocated into the highest-return services and whether investment assets are helping or muddying the story.

The price history follows those fundamentals. Tigermed’s rerating during the China-biotech boom reflected both earnings growth and multiple expansion. The subsequent slump reflected both earnings disappointment and a market-wide fall in what investors would pay for outsourced R&D growth. The company’s current A-share still sits far below the peak optimism embedded in the 2020–2021 period, even after the 2025–2026 recovery trade. That shift looks mostly structural: the market now demands cleaner profit and more visible order conversion before granting the sort of top-tier multiple it once awarded almost automatically to Chinese CRO names.

Business model and industry

Revenue structure and operating economics

Tigermed’s business engine has become broader, but the economics are uneven. In 2025, clinical trial solutions contributed RMB 3.27 billion of revenue, up 2.79% year on year, while clinical-related and laboratory services contributed RMB 3.45 billion, up 4.57%. The first segment generated only a 20.09% gross margin; the second generated 32.64%. Regionally, domestic business produced a 23.72% gross margin and overseas business 29.78%. That makes the strategic direction obvious. The company is trying to become less dependent on lower-margin domestic execution and more leveraged to higher-margin overseas and specialty work.

The cost structure explains why that transition is not frictionless. The annual-results presentation shows direct labor cost rising to 34.0% of revenue in 2025 from 33.8% in 2024, direct project-related costs rising to 25.2% from 20.7%, and overhead costs rising to 13.4% from 11.5%. Total cost of services rose faster than revenue, to 72.6% of revenue from 66.0%. In plain English, the company added or maintained capacity ahead of full utilization, and project mix moved in a less favorable direction. This is classic operating leverage in reverse. The encouraging part is that the same structure can work in favor once utilization and pricing improve.

The order book suggests that operating leverage may indeed be turning. Net new bookings rose 20.6% in 2025 and backlog 15.4%. The company’s deck also says domestic new-booking pricing stabilized, which matters because pricing, not just volume, was part of the sector reset. If that stabilization persists, margin recovery should lag bookings but eventually follow it. That is one of the most important timing questions for the stock.

Moat and management

Tigermed’s moat is real, but narrower than the broad “integrated platform” language often used in CRO marketing. The first real moat is embedded delivery infrastructure inside China clinical development. The company-cited figures on ongoing projects, site-management scale, and long participation in Class I new-drug approvals all point to accumulated execution data, site relationships, and sponsor familiarity. The second moat is regulatory and operating know-how across cross-border studies, especially MRCTs and overseas regional trials. At year-end 2025 the company had 48 ongoing MRCTs and 193 ongoing single-region overseas studies. The third moat is scale at the domestic-clinical layer: the larger the active-project base, the easier it is to amortize compliance systems, project-management platforms, and specialist teams.

The weaker moats are the ones investors should not overpay for. Tigermed does not have a pure technology moat in the way a proprietary-software vendor might. It does not have the manufacturing lock-in of a CRDMO like WuXi AppTec. It does not have a global commercial-data moat like IQVIA. Its AI tools and internal large-language-model platform may improve efficiency, but there is not enough disclosed evidence yet to treat them as a major profit moat. For now they are likely productivity aids, not a reason to rerate the stock by themselves.

Management has been bold in capital allocation, sometimes productively, sometimes opaquely. The positive side is that management did not stand still with a narrow China-only model. The Micron acquisition in Japan and hiring expansion in India and Malaysia are rational if the goal is to capture overseas growth and higher-margin global programs. The company has also shown willingness to support the stock in weak periods: after several earlier repurchase programs, it advanced a fresh 2026 buyback plan of RMB 500 million to RMB 1 billion, and later obtained a bank loan commitment of up to RMB 900 million specifically for repurchases. The negative side is that the founders’ disclosure investigation inevitably lowers management credibility in capital markets, even if day-to-day operations are unaffected.

Industry structure, cycle, and policy

China CRO demand is not one cycle. It is at least four cycles layered together: domestic biotech financing, multinational outsourcing into China, the global trial mix for Chinese-origin assets, and the utilization cycle in nonclinical and laboratory capacity. Tigermed sits most directly in the clinical-development and data-services parts of that system, which makes it less exposed to manufacturing policy risk than some peers, but still highly exposed to sponsor funding cycles and outsourcing budgets.

The industry evidence reviewed for this report supports the idea that demand improved in 2025, but it does not support a simplistic “everything is back” claim. Tigermed’s own JPM 2026 deck, citing PharmaCUBE and HGRAC data, showed faster growth in China clinical-trial IND approvals and Phase I initiations in 2025, and a continuing decline in the number of newly added clinical CROs since the earlier peak. That suggests a healthier market structure: more demand, fewer easy entrants, and less oversupply. But the same materials also show why customer quality matters. Large pharma and MNCs were increasing contributors to bookings, while pricing discipline had only stabilized rather than meaningfully rebounded. This is recovery, not euphoria.

Policy and geopolitics carry real weight here too. Chinese CROs face a heavier politics discount than the market once assumed. WuXi AppTec’s U.S. political and blacklist-related issues in 2026 are a reminder that global customers can reassess risk exposure to China-linked service providers for reasons unrelated to operating execution. Tigermed’s business mix is less directly exposed than WuXi’s manufacturing-linked platform, but not insulated. A customer diversification and geographic-footprint story helps only if customers believe the compliance and governance architecture is just as sound. That is another reason the founder disclosure issue matters more than a one-day chart might suggest.

Horizontal competitor analysis

The competitive map

This is a crowded field, so the right scenario is a peer set of several representative names rather than one or two direct one-for-one comparables. The most useful cross-section is not “which company also says it is a CRO,” but “which companies investors actually use to anchor quality, growth, and valuation.” On that basis, the most relevant set is WuXi AppTec inside China’s larger outsourced R&D universe; Pharmaron as a diversified Chinese all-stage service provider; JOINN as a more nonclinical-heavy Chinese comparator; Medpace as a global clinical-CRO quality benchmark; ICON as a global full-service comparator; and IQVIA as the scale benchmark for clinical research plus data.

Tigermed’s niche within that group is clearer than it first appears. It is strongest where clinical execution, site-management depth, China regulatory fluency, and increasingly cross-border trial management intersect. It is weaker where customers want a single provider from discovery through commercial manufacturing. That is why WuXi AppTec often captures a different profit pool. It is also weaker than IQVIA where payer data, commercial analytics, and real-world evidence scale are decisive. On the other hand, Tigermed is more internationally ambitious and more balanced than JOINN, and it is cheaper to choose for many China-and-Asia execution needs than a Western global CRO.

Group portrait of the peers

WuXi AppTec is a Chinese CRDMO with unusually high breadth. Its 2025 revenue reached RMB 45.46 billion, backlog in continuing operations rose 28.8% to RMB 58.0 billion, and the business sits far closer to the “every step of outsourced R&D and manufacturing” end of the spectrum. Customers choose it when breadth, chemistry, testing, and manufacturing handoff matter more than a pure-play clinical specialist. The risk in comparing Tigermed to WuXi is that doing so can flatter Tigermed’s valuation by putting it next to a structurally broader company.

Pharmaron is the diversified Chinese lifecycle-services platform. Its 2025 order intake grew more than 14%, and management guided 2026 revenue growth of 12% to 18%, reflecting both order momentum and a more balanced exposure across discovery, nonclinical, clinical, and commercialization support. Customers choose Pharmaron when they want one vendor to handle many adjacent development stages but still value a China-based cost and speed proposition. Tigermed competes with Pharmaron most directly in clinical development and related support, but Pharmaron’s broader stage coverage gives it more internal cross-selling room.

JOINN remains the preclinical specialist that has tried to broaden outward. Its official website still emphasizes nonclinical safety evaluation as the core identity, calling itself the largest nonclinical safety-assessment provider in China. Investors use JOINN as a comparator mainly to judge how much nonclinical-lab exposure is worth in the current cycle. That matters because Tigermed’s lab businesses partly pull it into the same debate over capacity utilization and return on fixed assets. Customers pick JOINN where GLP toxicology and related nonclinical work dominate. They do not primarily pick it for the same reasons they pick Tigermed.

Medpace is the cleanest clinical-CRO comp in the group. It reported solid fourth-quarter 2025 revenue growth to USD 708.5 million, net new business awards up 39.1%, and year-end backlog up 4.3% to USD 3.03 billion. Medpace customers often choose concentration and execution discipline over maximum breadth. That is why Medpace typically gets respect for earnings quality and order conversion. Against Medpace, Tigermed looks broader geographically within Asia but materially noisier financially.

ICON is the global full-service scale comparator, but 2026 also reminded investors how quickly a quality assumption can break. ICON’s 2025 revenue was USD 8.25 billion, free cash flow USD 862 million, and full-year net book-to-bill 1.09, but an internal accounting investigation disclosed in February 2026 later drove a major selloff and delayed confidence in reported numbers. The lesson for Tigermed is not that the two situations are identical. It is that service businesses trading on trust and future conversion can lose valuation support very quickly when governance or accounting questions appear.

IQVIA is the scale-and-data benchmark. Its 2025 revenue was USD 16.31 billion, with Technology & Analytics Solutions at USD 6.63 billion and Research & Development Solutions at USD 8.90 billion. Customers choose IQVIA when they need global trial execution married to data, analytics, evidence, and commercialization tools. Tigermed cannot match that breadth. What it can offer instead is a more specialized, often more cost-effective operating model in China and adjacent overseas markets. That keeps it relevant. It does not justify a valuation on IQVIA-like terms.

A narrow valuation snapshot helps show where Tigermed stands today. The numbers below mix local quote sources and CNY conversions where needed; they are for cross-sectional comparison, not for precision trading. The bigger point is that Tigermed’s A-share is not obviously bargain-priced against either Chinese or global peers once one adjusts for its messier earnings quality.

† Entity value on A-share price basis, using total shares outstanding and the 2026-07-15 A-share close. ‡ Converted at USD/CNY 6.7624 on 2026-07-15.

What these numbers say in business terms is simple. Tigermed is not being priced like a distressed service company. Nor is it being priced like the global scale leaders with cleaner economics. It sits in the awkward middle: expensive enough that investors already expect real earnings repair, but not trusted enough to command the multiple of the group’s cleanest names without cleaner proof.

Current fundamentals and valuation

Last four quarters and the market’s current narrative

The last four reported quarters show why the stock is hard to read from a single headline. In 2025, quarterly revenue rose each quarter from RMB 1.56 billion in Q1 to RMB 1.81 billion in Q4, but attributable profit swung from positive in the first three quarters to a Q4 loss of RMB 132.5 million. Ex-non-recurring profit stayed positive in every quarter, including RMB 29.1 million in Q4. In Q1 2026, revenue rose to RMB 1.80 billion, attributable profit dropped to RMB 49.0 million, but ex-non-recurring profit rose to RMB 120.4 million and operating cash flow rose to RMB 317.7 million. The market is effectively choosing which line to believe.

The healthier interpretation is that core operating demand improved into 2026 but statutory profit remains distorted by two factors: non-core valuation items and minority-interest allocation. In Q1 2026, group net profit was RMB 330.1 million, but minority shareholders were allocated RMB 281.0 million, leaving only RMB 49.0 million attributable to the parent. That kind of mismatch is not fatal, but it does make standard P/E analysis less useful unless the investor normalizes earnings.

The market is therefore trading three overlapping narratives at once. One is cyclical recovery in China and cross-border R&D demand. The second is overseas mix improvement, because overseas business still carries better gross margins than domestic work. The third is governance repair after the founder disclosure case. The first two are fundamental narratives. The third is a capital-markets narrative. Right now, the stock seems to move most when that third one changes, even though the first two will decide long-term value.

Valuation analysis

The first step is to reject headline net profit as the sole valuation anchor. In 2025, operating cash flow was RMB 1.118 billion, reported attributable profit RMB 887.9 million, and adjusted attributable profit only RMB 355.1 million. The long-run passthrough from accounting earnings to cash is therefore unstable because the “E” keeps moving with investment income, fair-value changes, and other non-recurring items. The annual report itself is explicit that investment income and fair-value changes materially affected profit. For valuation, the safer base is normalized operating earnings somewhere between depressed adjusted profit and fully recovered clean earnings power, not the 2025 headline EPS of CNY 1.04.

The historical-valuation problem is easy to state. On headline trailing EPS, the A-share looks expensive but not absurd; on adjusted 2025 earnings it looks extremely expensive. That does not mean the stock is automatically overvalued. It means the stock is already monetizing a forward recovery, not trailing reality. A large part of the upside case therefore depends on the market being right about normalization.

Peer valuation offers only limited comfort. Pharmaron trades on a lower multiple with broader stage coverage. Medpace and IQVIA carry lower or similar broad multiples, with cleaner earnings histories and stronger global customer diversification. JOINN commands a higher multiple, but that says more about the market’s willingness to speculate on sharp cycle recovery in smaller Chinese CRO names than about a safe valuation floor for Tigermed. Tigermed’s premium to the H-share line is also a warning sign. Using the 2026-07-15 closes and the HKD/CNY rate of 0.8635, the A-share traded at roughly a 54.5% premium to the H-share. That is too wide to ignore.

The absolute-valuation framework below uses normalized attributable profit rather than reported 2025 profit. That choice is deliberate. It assumes the business is recovering from a weak cycle, but it refuses to capitalize one-off investment gains as if they were recurring CRO earnings. This is valuation-scenario analysis within a research framework, not investment advice.

Inputs use 861.03 million total shares outstanding and current A-share pricing as the base for per-share valuation.

The real conclusion from that table is not the exact midpoint. It is the shape. A lot of the downside comes from multiple compression if the market decides recovery is real in bookings but insufficient in clean earnings. A lot of the upside requires Tigermed to prove that bookings growth, overseas mix, and lab utilization can all improve together, while the governance issue does not leave a lasting scar on valuation.

Expectation-gap analysis points to three metrics the market now cares about most. First, new bookings and backlog growth need to stay positive. Second, domestic versus overseas margin spread needs to hold or widen in the right direction. Third, attributable profit needs to converge toward core operating profit rather than being distorted by fair-value and minority-interest noise. If the next earnings cycle shows those three moving together, the bull case strengthens sharply. If bookings stay good but attributable EPS remains noisy, the stock can go nowhere for a long time.

Margin-of-safety discipline gives a cautious answer. At the current A-share price, there is no discount to the conservative scenario. The most fragile assumption in the base case is not revenue growth by itself. It is normalized margin recovery. If that recovery reaches only about 70% of the base-case improvement, the base-case valuation slips back toward the low-40s. In a flat-earnings world, current buyers are relying on the multiple staying generous. That is not a margin of safety. It is an assertion of confidence. The verdict is not obvious.

Key data tables

The table below shows the operating split between the clean story and the noisy story.

Amounts are RMB billions except where noted; bookings and backlog are year-end presentation figures.

The business reason behind these numbers is straightforward. By 2025, demand had stopped collapsing, bookings had turned up, and cash generation was healthy. What had not recovered yet was clean attributable earnings. That is why the stock feels stronger than the headline P&L suggests, but also riskier than the cash-flow statement suggests.

Risk, catalysts, tracking dashboard, research uncertainties, and sources

The biggest permanent-capital risks are specific, not abstract. The first is a false recovery in domestic clinical outsourcing. Probability medium, impact high. The observable indicator is whether bookings stay positive while average selling prices and clinical-trial-solutions margin continue to slip. If domestic Phase I/II pricing weakens again after management’s claim of stabilization, the market will conclude 2025 was a restocking bounce, not a durable turn. That would hit revenue quality, gross margin, and the valuation multiple at once.

The second is earnings-quality failure. Probability medium, impact high. As long as reported profit depends heavily on investment income, fair-value movements, and minority-interest allocations, investors cannot underwrite a clean earnings multiple. The risk is not insolvency. It is that the stock never rerates because the market refuses to trust the “E” in P/E. The observable indicators are the share of profit before tax coming from investment and fair-value items, and the gap between group net profit and parent-attributable net profit.

The third is governance discount persistence. Probability medium, impact high. The trigger is not simply the existence of the CSRC case. The trigger is whether it ends in a way that convinces investors the issue was narrow and historical, or whether it reveals broader weaknesses in disclosure controls. A disappointing outcome would weigh mostly on valuation, but could also affect customer confidence at the margin.

The fourth is overseas-execution misread. Probability medium, impact medium to high. Tigermed’s overseas mix is one of the strongest parts of the bull case because overseas gross margin remains higher than domestic. If overseas growth slows, or acquisition integration in Japan and other markets underdelivers, the company loses the easiest path to mix-driven margin recovery. The observable indicators are regional revenue mix, overseas gross margin, and ongoing overseas trial counts.

The positive catalysts are also concrete. Sustained booking growth above revenue growth would show backlog is still deepening. A second catalyst would be a visible rebound in clinical-trial-solutions gross margin, because that would say pricing and utilization are both improving. A third would be evidence that overseas projects and MRCTs continue to climb without margin sacrifice. A fourth would be a clean closure of the founder-disclosure matter. A fifth would be continued buyback execution at depressed prices, because the company has both authorization and financing support to do it.

The tracking dashboard below is the short list that matters.

§ Market calendars reviewed for this report list around 2026-08-29; an exact formal company notice date was not identified in the sources reviewed.

There are four important research uncertainties. The company does not explicitly split maintenance and growth capex in a way that lets an outside analyst build a precise owner-earnings model from filings alone. Official company materials give ample year-end 2025 evidence on bookings and headcount, but not an equally crisp mid-2026 operational update outside the first-quarter report. Current official company materials support a 42-country figure at 2025 year-end and a 43-country figure on the live locations page, but not the “roughly 50 countries” language found in secondary reporting. Finally, the founder case is live enough that its eventual regulatory outcome remains unknown.

The primary sources used for this report were the 2025 annual report, the 2026 first-quarter report, the 2025 annual-results presentation, the JPM 2026 presentation, the company’s global-locations page, the A-share and H-share disclosures on the founders’ investigation, the 2026 buyback circular, and official or primary peer materials from WuXi AppTec, Pharmaron, Medpace, ICON, and IQVIA.

Cross-synthesis summary

Looking across the whole journey, the capability Tigermed has genuinely proven is not generic “platform strength.” It has proved that it can organize and execute highly fragmented, heavily regulated clinical-development work at scale, first inside China and then increasingly across borders. That is a different statement from saying it can dominate every outsourced R&D layer. It cannot. But it has shown that it can become deeply embedded in one of the hardest parts of drug development: turning protocols into compliant, monitored, multi-site, multi-country execution. That capability survived the downcycle. The order book growth in 2025 and the better cash flow in Q1 2026 say the franchise did not lose relevance when the easy biotech money disappeared.

Its past success came from a mix of structural tailwind and management skill. The structural tailwind was China’s rapid emergence as a serious innovative-drug market and the corresponding need for outsourced clinical infrastructure. Management skill mattered in turning that backdrop into a scalable business, widening the service stack, and listing in both Shenzhen and Hong Kong at moments when capital was available. What did not work as well was the transition from fast revenue scaling to clean return scaling. The 2022–2025 reset exposed where management had leaned too far into complexity: lab utilization, acquisition digestion, and an investment portfolio that helped earnings in some periods and obscured them in others.

Those success factors are still present today, but in altered form. China remains a crucial trial geography. Multinationals still need local execution. Chinese-origin assets are still going overseas. The company’s own materials show overseas and MRCT activity remains meaningful, and overseas margins remain better than domestic margins. But capital markets are valuing the same business differently now. They no longer pay a premium simply because the company sits in a hot outsourcing segment. They want proof that bookings turn into clean parent-level earnings, and that governance risk is contained. That is the new bar.

Horizontally, Tigermed’s real advantage versus competitors is still its position at the center of China clinical development, plus a now-material overseas operating layer. Customers choose it when they need a China-rooted partner that can also help them run transnational programs without paying for a fully global mega-platform like IQVIA. They choose WuXi AppTec when manufacturing adjacency matters, Medpace when they want a cleaner clinical pure play, and Pharmaron when they want wider stage coverage. Tigermed’s weakness is not a lack of relevance. It is that the capital market has to do more work to understand where profit is really coming from. That weakness is partly temporary, because utilization and cycle can improve. It is partly structural, because the group is more complex than its old “clinical CRO” description implies.

The current A-share valuation rewards future repair more than past performance. That is the key bottom line. The business today is better than the trough-year profits suggest, but the share price already assumes that better business will show up in the income statement more clearly over the next several reporting cycles. The H-share discount reinforces the point. If one line of the same legal entity trades at a mid-50s-percent discount on a CNY-converted basis, the burden is on the A-share bull to explain why domestic investors should continue paying that premium after a governance shock and before normalized EPS has decisively reappeared. There are reasons they might. There is not much margin for error if they do not.

What the market is most likely misjudging right now is the order in which recovery happens. Markets want earnings first and margin later. Tigermed may recover in the opposite sequence: bookings first, then cash flow, then utilization, then cleaner attributable earnings. If that is right, the stock can look “not cheap” for a while even as the business improves underneath it. That is not a broken thesis. It is just a reason to be price-sensitive.

The decisive variables differ by horizon. Over the next year, what matters most is conversion: do brisk bookings and better first-quarter cash flow turn into cleaner interim and full-year earnings. Over three years, the question is mix: can overseas and specialty services become large enough to pull the whole group margin upward. Over five years, the question is identity: does Tigermed become a genuinely international clinical-development platform with China as its base, or does it remain perceived as a China cyclical with overseas satellites.

The company would become a better investment under three conditions. One is price: a clear discount to the conservative valuation case. Another is quality: two or more consecutive periods in which ex-non-recurring profit, reported attributable profit, and cash flow all point in the same direction. The third is governance: enough resolution of the founder case that the market can stop guessing whether a permanent discount is warranted. Any of those conditions would help. All three together would transform the case.

Bull and bear reasons

Bull reasons

• Bookings and backlog finally turned up again in 2025, with net new bookings up 20.6% and backlog up 15.4%, which is the strongest single piece of evidence that the operating trough is behind the company.
• Overseas business is not cosmetic: by 2025, offshore revenue was 45.8% of total and carried a gross margin of 29.78% versus 23.72% domestically, giving the group a realistic path to mix-led margin improvement.
• Q1 2026 showed the kind of recovery underneath the headline that bulls care about, with revenue up 15.2%, ex-non-recurring attributable profit up 17.7%, and operating cash flow up 60.5%.
• The company still occupies a durable niche in China clinical development, with 663 ongoing drug clinical research projects at year-end 2025 including 241 overseas projects and 48 MRCTs.
• Capital allocation is at least partly shareholder-aware in the downturn, with a fresh 2026 buyback authorization of RMB 500 million to RMB 1 billion and a dedicated bank loan commitment for repurchases.

Bear reasons

• Clean earnings are still weak: adjusted attributable profit fell 58.5% in 2025 to RMB 355.1 million even though reported attributable profit rebound made the statutory picture look better.
• Earnings quality is still compromised by non-core items; in 2025 investment income was RMB 433.8 million and fair-value gains RMB 42.3 million, together a large share of pre-tax profit.
• The gross-margin repair is incomplete, with total gross margin down to 27.4% in 2025 from 34.0% in 2024 and the core clinical-trial-solutions segment at only 20.09%.
• Governance now deserves a discount because the controlling shareholders were placed under CSRC investigation over historical disclosure matters, and the stock’s sharp May 2026 drop shows investors take that seriously.
• The A-share already prices in a meaningful part of the recovery and still trades at a wide premium to the H-share, leaving little room for disappointment if normalized EPS arrives slower than hoped.

Pre-mortem

One plausible three-year loss script is a slow-conversion failure. Orders keep growing in the high single digits, but domestic pricing never really improves, so the clinical-trial-solutions segment stays around a 19%–20% gross margin instead of recovering into the mid-20s. Overseas growth helps, but not enough to offset weak domestic mix. Normalized attributable earnings stall around CNY 0.9 to 1.0 per share. The market, tired of waiting and still applying a governance discount, cuts the acceptable multiple from about 40x to about 25x–28x. A CNY 51.9 stock becomes a low-30s stock. That is a roughly 40% drawdown without any collapse in revenue.

A second script is a sharper credibility break. The founder disclosure case resolves badly enough to imply weaker disclosure controls than the market assumed. At the same time, investment and fair-value contributions retreat, so the gap between operating cash flow and parent-attributable earnings becomes harder to explain away. The market stops giving Tigermed the benefit of the doubt as a recovering quality name and starts valuing it more like a governance-risk cyclical. If normalized EPS is around CNY 1.0 and the multiple compresses to 20x–22x, the downside could approach 50% from current A-share levels.

Final research conclusion

Tigermed is worth respecting as a business and approaching carefully as a stock. The business has real franchise value. It remains embedded in China clinical development, it has widened its overseas footprint enough to matter, and the 2025–2026 operating indicators support the case that demand has inflected upward again. But the stock cannot be valued on brand and backlog alone. It still has to earn back investor trust on clean parent-level earnings and governance. At today’s A-share price, investors are not buying a washout. They are buying the recovery before it has fully shown up in normalized EPS.

That leaves the shares in an uncomfortable but investable middle ground. I do not think the bear case that treats Tigermed as a structurally damaged franchise fits the evidence. I also do not think the A-share offers enough margin of safety to call it a clear buy. The strongest evidence now sits in bookings, backlog, overseas mix, and cash flow. The weakest evidence sits in earnings quality and governance. What would change my mind in a positive direction is a combination of lower price and cleaner proof: several periods of bookings converting into margin and attributable profit, with no fresh governance damage. What would change my mind in a negative direction is evidence that revenue recovers while the economic return on that revenue does not.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium-low
• Valuation attractiveness: low
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: Bookings are recovering and overseas mix helps, but the A-share already prices much of the recovery while earnings quality and governance still need proof.
• 【Ideal Buy Price】24–27 CNY Basis: at least a 20% margin of safety below the conservative valuation case of roughly CNY 31-33.
• Acceptable hold price: 43–58 CNY
• Clearly overvalued price: 79–86 CNY
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A buy becomes more compelling below CNY 27, ideally with evidence that ex-non-recurring profit and reported attributable profit are converging upward. The opportunity cost of waiting is missing a faster-than-expected rerating if overseas margins and backlog conversion accelerate.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about -13% to -15%; base about flat to +3%; optimistic about +11% to +14%
• Max-loss risk: about 40% to 50%, triggered by a combination of stalled margin recovery, governance discount persistence, and multiple compression toward the mid-20s on normalized earnings
• Reassessment-trigger signals:
  • if net new bookings turn flat or negative for two consecutive reporting periods
  • if clinical-trial-solutions gross margin falls below 20% for two consecutive periods
  • if investment income plus fair-value changes remain above one-third of pre-tax profit over a full year
  • if overseas gross margin premium over domestic compresses below 2 percentage points
  • if the founder disclosure case produces findings that point to broader control failures

【Valuation Range】

• current: 51.90 (close as of 2026-07-15)
• bear (conservative · ideal buy zone): [24, 27]
• base (fair · acceptable hold zone): [43, 58]
• bull (optimistic · above the clearly-overvalued line): [79, 86]

Other tickers mentioned

• 603259.SHG — WuXi AppTec, the broadest Chinese CRDMO comparator and a useful benchmark for sector recovery and backlog strength
• 300759.SHE — Pharmaron, the closest diversified Chinese lifecycle-services peer in the domestic CRO universe
• 603127.SHG — JOINN, a nonclinical-heavy Chinese comparator that helps frame utilization and lab-cycle risk
• MEDP.US — Medpace, the cleanest global clinical-CRO benchmark for earnings quality and order conversion
• ICLR.US — ICON, a global full-service CRO comparator and a reminder of how governance or accounting issues can crush valuation
• IQV.US — IQVIA, the global scale benchmark in clinical research plus data and analytics
• 02269.HK — WuXi Biologics, not a direct clinical peer, but relevant to broader China biopharma-outsourcing sentiment and valuation

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.